Fluxome has appointed Angela Tsetsis, former vice president of Martek/DSM, as its new CEO. She brings more than 25 years of experience from the nutritional and food ingredient industry and will be responsible for continuing the positive development of the company with the aim of becoming the leading global provider of resveratrol as well as a key player in the nutraceutical ingredient industry.
Mrs. Tsetsis was among the key individuals to transform the successful ingredient company Martek (now part of Royal DSM) from a small entrepreneurial company to a leading global company with a turnover of close to USD 500 M. In her latest role she took up the position as VP, Corporate Strategy, with a broad responsibility for all commercial business units.
With Mrs. Tsetsis' global experience in bringing innovative products to the market along with her ability to utilize cutting edge fermentation technologies she is set to build on Fluxome's existing platform, accelerate growth in sales of existing products such as Fluxome Resveratrol, and commercialize the promising product pipeline in Fluxome.
The new CEO states: "I am ready to take Fluxome to the next level and utilize the massive potential of one of the most promising and innovative companies in the nutraceutical ingredient industry. I am confident that Fluxome can become the leading company in the resveratrol market and a key player in the nutraceutical industry over time.”
Fluxome is already in the process of penetrating the US market and has just launched Fluxome Resveratrol in Europe after obtaining Novel Foods Approval. Jarne Elleholm, Chairman of the Board is excited to bring the new CEO on board: "Angela Tsetsis is the perfect match for Fluxome. In the past she has proven how she is able to play a central role in growing a company to become a world-leading player in the nutraceutical arena.”